Kang Muslim
The Evolution of Cannabis Use and Legalization in the United States
The findings arrive at a pivotal moment in American history. Products derived from the Cannabis sativa plant have been part of the nation’s social fabric for centuries, with recreational use documented as far back as the mid-1800s. However, the trajectory of its consumption has been marked by dramatic shifts in both legality and social acceptance. During the alcohol prohibition of the 1920s, cannabis emerged as a popular alternative, leading to the first major wave of federal regulation with the Marihuana Tax Act of 1937. The counterculture movement of the 1960s further solidified the drug’s place in the American zeitgeist, even as it was classified as a Schedule I substance under the Controlled Substances Act of 1970.
By early 2025, the landscape has transformed entirely. Recreational cannabis is now legal in 24 states and the District of Columbia, and recent surveys indicate a historic shift in consumption patterns: daily cannabis use among Americans has now surpassed daily alcohol consumption. This expanded access has led to a rise in clinical cases of cannabis use disorder, a condition characterized by an inability to cease consumption despite significant interference with health, social obligations, or physical safety. While the link between cannabis and mental health issues—specifically psychosis—was first suggested in medical literature in the early 20th century and bolstered by a 1987 study of 45,000 Swedish army recruits, the specific comparative risks between cannabis and other substances remained under-researched until now.
Methodology: The TriNetX Analysis and Propensity Score Matching
The research was spearheaded by Ryan C. Nicholson, a medical resident at the Johns Hopkins University School of Medicine, and Johannes Thrul, an associate professor at the Johns Hopkins Bloomberg School of Public Health. The team’s motivation was rooted in the real-world clinical shifts they observed following the legalization of recreational cannabis in Maryland in 2023. To understand the unique psychiatric footprint of cannabis, the team analyzed nearly 700,000 medical records from the TriNetX commercial database, which aggregates data from various healthcare organizations.
To ensure the study’s findings were robust, the researchers employed a statistical technique known as propensity score matching. This method is essential in observational studies to minimize bias; it pairs individuals from different groups—in this case, those with cannabis addiction versus those with other substance addictions—who share nearly identical backgrounds. By matching patients based on age, sex, ethnicity, income level, and prior health history, the researchers were able to isolate the impact of the specific drug addiction on subsequent mental health diagnoses. The study divided the subjects into two primary cohorts: a group of 691,806 adults and a pediatric group of 49,586 youths aged 17 and under.
The Adolescent Crisis: Heightened Vulnerability to Psychosis and Depression
The data regarding pediatric patients presented a sobering picture of adolescent vulnerability. Among those aged 17 and under, the median age for cannabis addiction was 16. The study found that these adolescents were 52 percent more likely to be diagnosed with schizophrenia than their peers who were addicted to other substances, such as alcohol or stimulants. The psychiatric toll extended beyond psychosis; the cannabis-addicted youth also faced a 30 percent higher risk for recurrent major depression and a 21 percent higher risk for anxiety disorders.
A particularly striking finding was that approximately 10 percent of the patients in the addiction categories were under the age of 12. This aligns with broader clinical data suggesting that roughly 10.2 percent of adult addicts began their substance use at age 11 or younger. For these children and young teenagers, the introduction of cannabis occurs during a critical window of neurological maturation. The researchers noted that these early exposures provide a foundation for long-term adverse health outcomes, effectively altering the trajectory of their mental health before they even reach adulthood.
The Adult Paradox: Lower Relative Risk and Nuanced Comparisons
In a surprising contrast to the adolescent data, adults addicted solely to cannabis exhibited a lower risk of developing most psychiatric conditions compared to adults addicted to other substances. Specifically, the cannabis group showed a 19 percent lower risk for schizophrenia (0.34 percent versus 0.42 percent in the other substance group). Adults in the cannabis group also saw lower rates of subsequent psychosis, recurrent major depression, and suicide attempts.
However, when the data was broken down by specific substances, the results became more complex. When compared directly to alcohol, cannabis users had a lower risk of depression and psychotic disorders. When compared to cocaine users, cannabis users had lower rates of schizophrenia and depression but significantly higher rates of anxiety. The comparison with opioid addiction revealed yet another variation: while cannabis users had lower rates of depression and anxiety than opioid users, they had a slightly higher risk of developing schizophrenia. Even in adults who struggled with multiple drug addictions simultaneously, those whose "cocktail" included cannabis often showed lower rates of schizophrenia, depression, and bipolar disorder than those addicted to multiple non-cannabis substances.
Biological Mechanisms: The Endocannabinoid System and the Developing Brain
The researchers proposed several biological explanations for why teenagers are so uniquely susceptible to the negative psychiatric effects of cannabis. The human brain houses the endocannabinoid system, a complex network of receptors and signaling molecules that regulate mood, memory, and cognitive development. During adolescence, the concentration of these receptors peaks in the prefrontal cortex—the area of the brain responsible for executive function, complex decision-making, and social behavior.
Introducing external cannabinoids (like THC) during this period may "hijack" or alter the maturation process of the prefrontal cortex. This disruption can predispose young people to schizophrenia and other psychiatric disorders that they might not have developed otherwise. Dr. Thrul noted an "acceleration effect," where heavy cannabis use might trigger the onset of these illnesses earlier in life for those already predisposed. This phenomenon might also explain why the relative risk appears lower in adults; many individuals who were vulnerable to cannabis-induced psychiatric issues may have already been diagnosed during their youth, leaving a "hardier" population of adult users.
Analysis of Implications: Policy, Education, and the Self-Medication Debate
One of the most critical considerations raised by the study is the direction of cause and effect. While the data shows a strong correlation between cannabis use and mental illness in youth, Dr. Thrul cautioned that the relationship could be bidirectional. It is possible that individuals who are innately more likely to develop psychiatric disorders seek out cannabis as a form of self-medication to cope with early, sub-clinical symptoms of their illness. This "prodromal" phase of mental illness often involves social withdrawal and anxiety, which some users may attempt to alleviate with marijuana.
From a public health perspective, these findings suggest that a "one-size-fits-all" approach to drug education is insufficient. Current public health messaging often focuses on the general risks of "drugs," but this research argues for a specific, high-intensity focus on the risks to the developing brain. As high-potency cannabis products—some containing upwards of 90% THC—become more prevalent in legal markets, the risk to adolescents may be even higher than what was captured in this historical data.
Limitations and the Path Forward for Research
Despite its scale, the study has limitations inherent to observational research based on medical records. The TriNetX database relies on diagnostic codes entered by various physicians, which may lack the granular detail of a patient’s full history. Crucially, the records did not specify the type of cannabis consumed or its potency, making it difficult to determine if the rise of "shatter," "wax," or high-THC edibles is driving the increased risk in youth.
Future research is expected to utilize brain imaging technology to observe the physical structural changes in the developing brain following long-term cannabis exposure. Additionally, pathology studies may help map the cellular changes that occur in the prefrontal cortex. For now, the message from the research community is clear: while the risks for adults may be lower relative to other substances, the danger for the younger generation is pronounced. "I would never recommend that teenagers use cannabis, especially not the high-potency cannabis products that are on the market now," Thrul concluded. The study serves as a vital reminder that in the era of legalization, age remains the most significant factor in the safety profile of cannabis.
